Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Treasury Shares (2020 - 2025)

Aclaris Therapeutics has reported Treasury Shares over the past 6 years, most recently at $2.2 million for Q4 2025.

  • Quarterly results put Treasury Shares at $2.2 million for Q4 2025, up 1111.05% from a year ago — trailing twelve months through Dec 2025 was $2.2 million (up 1111.05% YoY), and the annual figure for FY2025 was $2.2 million, up 1111.05%.
  • Treasury Shares for Q4 2025 was $2.2 million at Aclaris Therapeutics, down from $3.1 million in the prior quarter.
  • Over the last five years, Treasury Shares for ACRS hit a ceiling of $3.1 million in Q1 2024 and a floor of $2375.0 in Q2 2022.
  • Median Treasury Shares over the past 5 years was $1.6 million (2022), compared with a mean of $1.7 million.
  • Biggest five-year swings in Treasury Shares: surged 72322.74% in 2023 and later tumbled 92.48% in 2025.
  • Aclaris Therapeutics' Treasury Shares stood at $1.5 million in 2021, then increased by 2.09% to $1.5 million in 2022, then increased by 0.08% to $1.5 million in 2023, then tumbled by 88.17% to $180000.0 in 2024, then soared by 1111.05% to $2.2 million in 2025.
  • The last three reported values for Treasury Shares were $2.2 million (Q4 2025), $3.1 million (Q3 2025), and $3.1 million (Q2 2025) per Business Quant data.